

**Unclassified**

**English - Or. English**

**8 December 2021**

**ENVIRONMENT DIRECTORATE  
CHEMICALS AND BIOTECHNOLOGY COMMITTEE**

**Cancels & replaces the same document of 3 September 2021**

**Guidance Document for the scientific review of Adverse Outcome Pathways**

**Series on Testing and Assessment,  
No. 344  
Series on Adverse Outcome Pathways  
No. 20**

**JT03487133**

**SERIES ON TESTING AND ASSESSMENT  
NO. 344**

**Guidance Document for the scientific review of Adverse Outcome Pathways**

**IOMC**

**INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS**

A cooperative agreement among **FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD**

Environment Directorate  
ORGANISATION FOR ECONOMIC COOPERATION AND DEVELOPMENT  
Paris 2021

## About the OECD

The Organisation for Economic Co-operation and Development (OECD) is an intergovernmental organisation in which representatives of 36 industrialised countries in North and South America, Europe and the Asia and Pacific region, as well as the European Commission, meet to co-ordinate and harmonise policies, discuss issues of mutual concern, and work together to respond to international problems. Most of the OECD's work is carried out by more than 200 specialised committees and working groups composed of member country delegates. Observers from several countries with special status at the OECD, and from interested international organisations, attend many of the OECD's workshops and other meetings. Committees and working groups are served by the OECD Secretariat, located in Paris, France, which is organised into directorates and divisions.

The Environment, Health and Safety Division publishes free-of-charge documents in eleven different series: **Testing and Assessment; Good Laboratory Practice and Compliance Monitoring; Pesticides; Biocides; Risk Management; Harmonisation of Regulatory Oversight in Biotechnology; Safety of Novel Foods and Feeds; Chemical Accidents; Pollutant Release and Transfer Registers; Emission Scenario Documents;** and **Safety of Manufactured Nanomaterials**. More information about the Environment, Health and Safety Programme and EHS publications is available on the OECD's World Wide Web site ([www.oecd.org/chemicalsafety/](http://www.oecd.org/chemicalsafety/)).

*This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations.*

The Inter-Organisation Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen co-operation and increase international co-ordination in the field of chemical safety. The Participating Organisations are FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote co-ordination of the policies and activities pursued by the Participating Organisations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment.

**This publication is available electronically, at no charge.**

**Also published in the Testing and Assessment [link](#)**

**For this and many other Environment,  
Health and Safety publications, consult the OECD's  
World Wide Web site ([www.oecd.org/chemicalsafety/](http://www.oecd.org/chemicalsafety/))**

**or contact:**

**OECD Environment Directorate,  
Environment, Health and Safety Division  
2 rue André-Pascal  
75775 Paris Cedex 16  
France**

**Fax: (33-1) 44 30 61 80**

**E-mail: [ehscont@oecd.org](mailto:ehscont@oecd.org)**

**© OECD 2021**

Applications for permission to reproduce or translate all or part of this material should be made to: Head of Publications Service, [RIGHTS@oecd.org](mailto:RIGHTS@oecd.org), OECD, 2 rue André-Pascal, 75775 Paris Cedex 16, France

OECD Environment, Health and Safety Publications

# Table of contents

Foreword	6
Abbreviations	7
1. Background: The OECD AOP Development Programme	8
1.1. Objectives of the AOP Development Programme	8
1.2. Development of AOPs under the OECD AOP Development Programme	8
2. Pre-requisite for the AOP scientific review	11
3. The AOP Scientific review	12
3.1. The management of the review: Review organiser and review manager	13
3.2. Conflict of interest	14
3.3. Call for reviewers and recruitment of candidate reviewers	14
3.4. Selection of reviewers from the pool of candidate reviewers	15
3.5. The review process	16
3.6. Public information related to the reviewers	17
4. Subsequent AOP endorsement by OECD	17
References	19
Annex 1: Example of a template for the development of an AOP scientific review report	20
Annex 2: Declaration of interest	21
<b>FIGURES</b>	
Figure 1. The three phases of the AOP development process	9
Figure 2. Detailed description of the AOP development process	10
Figure 3. Illustration of the AOP scientific review process	13

# Foreword

The Adverse Outcome Pathway (AOP) framework has been developed to facilitate the collection of mechanistic information derived from toxicological science in a structured manner, to assist in establishing causal relationships between molecular and cellular events that lead from stressor perturbation of the biology to adverse effects, and to identify critical data gaps in the understanding of those pathways.

AOPs are intended to help regulatory agencies and risk assessors utilise a broader range of mechanistic data concerning the effects of stressors on various test systems (e.g. *in silico*, *in vitro*, *in vivo*) for decision-making. The widespread acceptance of AOPs as a source of information to guide interpretation, generation and application of data from alternative methods depends on the confidence in the quality of the AOP and therefore, on the review process used to evaluate whether the scientific evidence underpinning the AOP is reliable, credible, and balanced and thus that the science used to inform policy is trustworthy.

In order to maintain the development of high quality AOPs, it is important to standardise the way in which AOPs are developed and reviewed while retaining an appropriate degree of flexibility to ensure efficiency. The existing Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways (OECD, 2018) focuses on practical aspects of AOP development and assessment. The objective of the present document is to provide guidance on the quality standards required for the scientific review of an AOP on the AOP-Wiki. It defines the core principles associated with AOP scientific review in order to enable consistent scientific reviews to be conducted, regardless of who is doing the review, and thus will facilitate OECD endorsement.

This Guidance Document has been developed by the Extended Advisory Group for Molecular Screening and Toxicogenomics (EAGMST) based on the experience gained with the AOP scientific review over the past years. It was circulated to the Working Party of the National Coordinators of the Test Guidelines Programme (WNT) and the Working Party on Hazard Assessment (WPHA) for a commenting round in July 2020. Comments were discussed and addressed by the EAGMST and the document was approved by the WNT and the WPHA by written procedure in June 2021. It is published under the responsibility of the Chemicals and Biotechnology Committee.

# Abbreviations

AOP: Adverse Outcome Pathway

AOP-KB: AOP Knowledge-Base (<https://aopkb.oecd.org/>)

AOP-Wiki: Collaborative Adverse Outcome Pathway Wiki (<https://aopwiki.org/>)

CBC: Chemicals and Biotechnology Committee

CRPPH: Committee of Radiological Protection and Public Health

EAGMST: Extended Advisory Group for Molecular Screening and Toxicogenomics

FAQs: Frequently Asked Questions

IATA: Integrated Approaches to Testing and Assessment

ITS: Integrated Testing Strategy

KE: Key Event

KER: Key Event Relationship

OECD: Organisation for Economic Co-operation and Development

SAAOP: Society for the Advancement of AOPs

WoE: Weight of Evidence

WNT: Working Group of the National Coordinators of the Test Guidelines Programme

WPHA: Working Party on Hazard Assessment

# 1. Background: The OECD AOP Development Programme

## 1.1. Objectives of the AOP Development Programme

1. The objectives of the chemical safety programme of the Organisation for Economic Co-operation and Development (OECD) are to assist countries in developing and implementing policies and instruments that make their systems for managing chemicals as efficient and robust as possible, while protecting human health and the environment.

2. In this context, the OECD launched in 2012 a new programme on the development of Adverse Outcome Pathways (AOP). The AOP concept is expected to guide decision-makers, such as risk assessors in their work to use existing and emerging information on the effects of chemicals on various test systems (e.g. *in silico*, *in vitro*, *in vivo*), and to target the generation of additional information for regulatory decision-making.

3. A variety of potential uses has been described for AOPs. AOPs can, for example, inform the work of the OECD Test Guideline Programme by describing the rationale for the use of particular methods and also by identifying potentially more predictive methods for development. AOPs can be used as a basis for developing an Integrated Approaches to Testing and Assessment (IATA) or an Integrated Testing Strategy (ITS) (OECD, 2016a). The Defined Approaches for skin sensitisation are also based on the corresponding AOP (OECD, 2012, 2016b). They can also be used for further development and application of alternative approaches, such as read-across, as well as in a number of other regulatory contexts, such as priority setting for further testing, hazard identification (e.g. EFSA-ECHA, 2018), classification and labelling, and risk assessment (OECD, 2017).


4. Any chemical or non-chemical stressors that perturb biological pathways and/or functions are part of the AOP framework. Although the scientific review principles apply to all stressors, endorsement processes may differ (e.g. AOPs should be chemical-relevant for OECD Environment Health and Safety endorsement - see paragraph 11 and section 4).

## 1.2. Development of AOPs under the OECD AOP Development Programme

5. The development of an AOP under the OECD AOP Programme consists of three main phases (*Figure 1*). The first phase is the assembly of the knowledge in the AOP-Wiki (Collaborative Adverse Outcome Pathway Wiki, <https://aopwiki.org/>; a module of the AOP Knowledge-Base AOP-KB; <https://aopkb.oecd.org/>). The second phase is the review of the AOP, the subject of this Guidance Document. The third phase is the endorsement of the AOP by the responsible OECD Committees.



Figure 1. The three phases of the AOP development process



### ***The role of the Extended Advisory Group for Molecular Screening and Toxicogenomics***


6. The OECD AOP Development Programme is guided by the Extended Advisory Group for Molecular Screening and Toxicogenomics (EAGMST) which is under the oversight of the Working Group of the National Coordinators of the Test Guidelines Programme (WNT) and the Working Party on Hazard Assessment (WPHA).

7. The EAGMST has primary responsibility for (i) examining AOP proposals and deciding on their inclusion in the work plan of the AOP Development Programme, (ii) reviewing the AOPs for their consistency with principles and guidance set out in the User's Handbook (OECD, 2018) and (iii) approving the release of AOPs to WNT and WPHA for endorsement (see section 4 for a description of the process), after the completion of the scientific review. In addition, many EAGMST members also play an active role in the development of AOPs. With the scientific review of the AOPs being possibly outsourced, the above listed responsibilities of the EAGMST will become even more prominent. The various points of control EAGMST has over the process via its subgroups and collective decisions ensures a transparent control of the AOP Development programme.

### The various steps and interlinkages between the parties involved in AOP development

8. Figure 2 provides an overview of the OECD AOP development process. The [OECD Secretariat](#) serves as a liaison between the various actors and steps.

Figure 2. Detailed description of the AOP development process



9. Assembly phase (*Step 1 Figure 2*): An AOP is assembled by its authors in the AOP-Wiki. This should be done in compliance with the AOP development principles (OECD, 2018). If the AOP is included in the OECD AOP development work plan (paragraphs 12-14), coaching in AOP development is offered to the authors by EAGMST (the [OECD Secretariat](#) can be contacted). AOP authors will subsequently update their AOP in the AOP-Wiki to address comments during the review and endorsement phases.

10. Review phase (*Steps 2 and 3 in Figure 2*):

- A compliance check (*Step 2 in Figure 2*) is performed by the coaches who provided support to the authors during the assembly phase.
- Scientific review (*Step 3 in Figure 2*): It is conducted after the AOP has been assembled in the AOP-Wiki and checked for compliance (see section 2).

11. Endorsement phase (*Steps 4 and 5 in Figure 2*): This phase is OECD-specific and requires approval by EAGMST that the AOP can be submitted to the WNT and WPHA for endorsement. This is followed by the declassification by the Chemicals and Biotechnology Committee (CBC) as a last step. The

endorsement phase is based on the outcome of the scientific review, as well as authors' responses and AOP revisions to address reviewer comments. The three-step endorsement of the AOP can involve further revisions from the AOP authors to address OECD-specific comments (see section 4). AOP endorsement is followed by the publication of the AOP on the OECD dedicated Series on AOPs in [i-Library](#).

## 2. Pre-requisite for the AOP scientific review

### Inclusion of a project in the OECD AOP Development Programme work plan

12. Developers of an AOP who wish their project to be included in the OECD AOP development work plan should submit a completed [AOP Project proposal form](#) via the OECD Secretariat to the EAGMST. The EAGMST decides whether the proposed AOP should be included in the OECD AOP development work plan, and submits it for consultation to WPHA/WNT to help assess regulatory relevance and raise awareness about AOP developments. WPHA/WNT may also help identify opportunities for collaboration between groups and consider how AOPs can be better aligned to support regulatory needs of countries and how resources can be focused.

13. In principle, the submission of a project proposal for inclusion of an AOP in the OECD AOP development work plan can be done before any of the three-phases in the development of an AOP (*Figure 1*); however, in practice, the submission of a project proposal is encouraged before assembly of the AOP into the AOP-Wiki platform, so that authors can benefit from the coaching provided by EAGMST (see paragraph 16).

14. Contributing to the AOP-Wiki via the OECD AOP Development Programme allows authors to be supported during AOP assembly, provides more visibility and confidence in the AOP developed, and facilitates its potential use by regulators and more broadly by the scientific community. It is however possible for scientists to initiate and assemble an AOP in the AOP-Wiki outside of the OECD AOP Development Programme. In particular, AOP developers can still make valuable contributions even if their AOP is covering aspects of biology that do not have immediate regulatory application. AOPs developed outside the OECD AOP Development Programme can receive ad-hoc mentoring from the Society for the Advancement of AOPs (SAAOP). Practical details on how to request author access, either via OECD or SAAOP requests, are provided on the AOP-Wiki -'[start a new AOP](#)' page.

### Coaching and compliance check

15. Before scientific review, AOPs assembled in the AOP-Wiki are checked for compliance (see paragraph 16) with the principles and guidance set out in the Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways (OECD, 2018). The Users' Handbook details how to structure the elements of an AOP in the AOP-Wiki, and provides guidance on how to assemble and assess the weight of evidence (WoE) supporting the AOP (OECD, 2018).

16. The compliance check approach has evolved over time and is now the final step of an individual support offered during the AOP assembly process. Until 2018, this compliance check was conducted by

experts within the EAGMST (so-called "internal review"), after the authors had assembled an AOP in the AOP-Wiki and notified EAGMST that it was ready for review. In 2019, EAGMST introduced a coaching process for the authors of an AOP, starting when an AOP project is accepted into the work plan. The coach, a member of the EAGMST who is familiar with AOP guidance and development, guides developers during the assembly phase and helps them to adhere to the AOP development principles. At the end of this process, the coach fills in a compliance check form that ensures that the requirements of the Users' Handbook are met and that the AOP can thus undergo scientific review. The coach will not participate in the scientific review as a reviewer to avoid any potential conflict of interest.


### 3. The AOP Scientific review

17. The scientific review of an AOP, developed in the AOP-Wiki, is initiated after completion of the Users' Handbook compliance check by coaches. It is based on the following principles:

- The scientific review should be independent
  - ✓ Avoid conflicts of interest
- The scientific review should be transparent
  - ✓ Transparent selection of reviewers through diverse recruitment channels – e.g. making use of OECD expert groups with expertise in relevant fields.
  - ✓ Public disclosure on AOP-Wiki or e.AOP.portal of the names of the reviewers, the collective outcome of their individual declaration of interest analysis, their comments and the responses of the AOP authors to the reviewers' comments
- The collective scientific expertise of the Review panel should cover the full scope of the AOP (e.g. technical, biological, toxicological aspects)
- The scientific review should address a standard set of pre-defined charge questions (see paragraph 30 below)

18. Figure 3 provides a simple diagram illustrating interactions and roles of the key players in the AOP scientific review process.

Figure 3. Illustration of the AOP scientific review process



Note: The review organiser which may be supported by a review manager is responsible to establish a review panel. This panel carries out the scientific review and provides reports to the organiser. Reviewers and organiser/manager discuss the review outcome with the authors of the AOP. Finally, the organiser/manager provides a report summarising the outcome of the scientific review. The scientific review reports are made publically available on the AOP wiki.

### 3.1. The management of the review: Review organiser and review manager

19. A review organiser is in charge of the organisation of the scientific review, as illustrated in Figure 3. It may necessitate providing financial or staff support for the various tasks to be completed. In the first years of the OECD AOP Programme, scientific reviews were organised by the OECD Secretariat. However, in principle, any organisation or individual can act as a review organiser and conduct an acceptable review by following the principles listed in paragraph 17 and further described in section 3. As appropriate, the OECD Secretariat, on an ad hoc basis, may consult with the WNT and the WPHA to identify potential review organisers.

20. Prospective review organisers are encouraged to inform the OECD Secretariat of their interest and intention to conduct a scientific review and in doing so can benefit from advice and potential support from EAGMST.

21. The review organiser may wish to delegate tasks to a review manager (e.g. internal staff, consultant, journal editor) who ensures coordination between the reviewers during the review and as necessary, between the AOP authors and the reviewers once reviewers have submitted their initial comments. The review manager should have sufficient general knowledge in the field of the AOP under review in order to be able to facilitate the review, but should not personally contribute to the review. The review manager should have no conflict of interests associated with the AOP under review and should

ideally be affiliated with an independent organisation (e.g. government body or scientific journal). It is acknowledged that the role of the review manager in the coordination of the review is highly valuable.

### 3.2. Conflict of interest

22. Confidence in the AOP evaluation process depends on a high scientific quality of the review and on an independent and transparent process throughout evaluation at any step. The scientific review needs to be free of any conflict of interest in order not to undermine the credibility of a future published AOP.

23. This Guidance Document adopts the definitions of a conflict of interest (COI) proposed by the US National Academies (National Academies, 2003) in the context of committees developing reports, but a model similar to that established for the Persistent Organic Pollutants Review Committee of the United Nations (United Nations, 2019) could also be used. COI is defined as being any financial or other interest that conflicts with the service of an individual because it (1) could significantly impair the individual's objectivity or (2) could create an unfair competitive advantage for any person or organisation.

24. Both financial and other interests are important (ICMJE, 2018). In the context of the AOP review, review organiser and reviewer COIs include, in addition to financial interests, having participated in the development of the AOP under review or having a collaboration with the AOP developer or being from the same team or laboratory as the AOP developer, because this is susceptible to impair the individual's objectivity (see paragraph 23).

25. The review organiser's responsibility is to ensure the quality and integrity of the review. A review should not be organised by a group/entity with a potential COI (i.e. groups/entities directly impacted financially or otherwise by the outcome of the review), which could result in the review being compromised. It is thus recommended that the review organiser requests EAGMST to check the absence of COI of the review organiser prior to the scientific review. Otherwise, absence of COI of the review organiser will be checked by EAGMST after the scientific review, before the AOP is submitted to WNT and WPHA for endorsement. A proposed declaration of interest form is available in Annex 2. Other conflict of interest forms that capture potential relevant conflicts could be utilised (e.g. [The International Committee of Medical Journal Editors disclosure of interest checklist](#), Persistent Organic Pollutants Review Committee of the United Nations, [World Health Organisation declaration of interests for WHO experts](#), [National Academies of Science Conflict of interest policies and procedures](#)).

26. Review managers and reviewers have to declare any interests that are relevant to the functions to be performed in the context of the review, in the form of a declaration of interest or a COI questionnaire on potential conflicts. This form serves to document whether interests are of a significantly conflicting nature, or may be perceived as such, thus potentially preventing participation in the review process of the AOP under consideration. The forms will be analysed by the review manager or organiser and the review report will include a general statement that the review organiser can confirm that there are no potential COIs of reviewers based on the analysis of the declarations made by the reviewers. If there is a COI, participation in the review is not possible. A proposed declaration of interest form is available in Annex 2.

### 3.3. Call for reviewers and recruitment of candidate reviewers

27. It is up to the review organiser to launch a call for relevant reviewers and contact a broad network of experts via various appropriate channels. If the credentials and qualifications of the candidate reviewers are not publicly available, a short CV will be requested. Situations where an AOP developer suggests potential reviewers should be avoided.

28. The call for reviewers can be made via various channels depending on the organisation responsible for the scientific review. For example, when the review is organised by the OECD Secretariat, the WNT is invited to nominate relevant experts via the different expert groups of the Test Guideline programme; independent scientific societies with access to subject matter expertise may also be solicited. The WNT and the WPHA will be consulted when a call for reviewers is circulated, in order to be given the possibility to nominate experts and thus broaden the pool of candidates for the review. This can be done in coordination with the OECD Secretariat.

### 3.4. Selection of reviewers from the pool of candidate reviewers

29. Following the call for reviewers, a balanced Review panel for the scientific review will be established by the review organiser. The EAGMST recommends Review panels of 3 to 5 reviewers. This ensures diversity of opinions but also a manageable and efficient process. The number of reviewers may be adapted to provide sufficient expertise to evaluate the entire pathway being reviewed.

30. The selection of the reviewers will be based on both individual and Review panel criteria. Prior work with AOPs is not required, since the review of the AOP should focus on the scientific aspects presented in this AOP. Once enrolled in the Review panel though, the reviewers will familiarise themselves with AOP principles (see para graph 31).

- Individual criteria:

- The reviewers' expertise should be relevant to the AOP under review, not only for the hazard/endpoint (i.e. the AO) but at the various levels of biological organisation of the key events leading to the AO. This can be evaluated, for example, by examining the publications that a candidate reviewer has authored or co-authored and their relevance to the AOP under review;
- The reviewers should have no conflict of interest.

- Review panel criteria

- Appropriate collective scientific expertise of the Review panel is needed to ensure that the various parts of the AOP are covered and can be fully evaluated, i.e. addressing the various levels of biological organisation characterised within the AOP for the relevant endpoint;
- Balanced representation of research and regulatory fields and affiliation (country/region level) is desirable, but should not be achieved at the expense of scientific expertise.

31. Prior to the review, the review organiser should ensure that the reviewers are sufficiently informed of the AOP conventions. This could be done by consulting some of the training material available on-line. Videos, slide presentations, kick off review webinars, OECD [webinars on AOPs](#), and/or the online training course could for example be consulted. This is available from the AOP-Wiki Forum, [section on AOP training](#), which includes current training resources. In addition, a full list of available AOP training at the Animal Free Safety Assessment is available under the Tox21 workstream, at this link: <https://www.afsacollaboration.org/tox21/get-trained/#training-resources>. Reading the available documentation, especially the Guidance Document on Developing and Assessing Adverse Outcome Pathways (OECD, 2017), the Users' Handbook (OECD, 2018) and the Frequently Asked Questions (FAQs) is also strongly recommended.

### 3.5. The review process

32. The online version of an AOP on the AOP-Wiki can evolve over time. Therefore, the AOP-KB offers the possibility to generate a “snapshot” of the AOP at a certain point in time, in the form of a versioned, date-stamped PDF document. An AOP snapshot generated before the start of the review is the document of reference that should be used for the review.

33. The scientific reviewers’ tasks are to:

- ✓ Take note of comments that may have been made on previous versions of the AOP during the compliance check; these are available in the discussion pages of the AOP in the AOP-KB;
- ✓ Review the scientific evidence that has been presented to substantiate the AOP;
- ✓ Respond specifically to the following charge questions (additional questions may be added on a case-by-case basis, for example depending on the outcome of the Users’ Handbook compliance check):
  1. Scientific quality:
    - Does the AOP incorporate all appropriate scientific literature and evidence?
    - Does the scientific content of the AOP reflect current scientific knowledge on this specific topic?
  2. Weight of evidence (WoE):
    - Is the WoE judgement/scoring well described and justified based on the evidence presented? If not please explain.
    - Please consider WoE for each Key Event Relationship (KER) and for the AOP as a whole.

34. Assessment criteria for performing the scientific review are provided in the Users’ Handbook (OECD, 2018). Reviewers should avoid recommending changes that, if adopted, would cause the AOP under review to lose compliance with the Users’ Handbook or with the Guidance Document.

35. The reviewers send written responses and comments back to the review organiser, who is responsible for review collation and correspondence with the AOP authors.

36. It is recommended that during the review phase and until the submission of the reviewers’ comments to the organiser of the review, the AOP authors are not informed of the membership of the Review panel and any direct communication between the reviewers and the authors should be avoided. After AOP organisers have received the reviewers’ comments however, interactions between authors and reviewers can be organised and are encouraged. Bringing together the reviewers and the AOP authors has proven to be helpful because it enables them to discuss, exchange views and share experience about the AOP after the review. It also facilitates the revision of the AOP by their authors, in line with the reviewers’ comments.

37. The reviewers’ comments are processed by the review organiser according to its organisation’s standard process. If no formal process exists, the outcome of the scientific review could take the form of a scientific review report (see example of a template in Annex 1).



### 3.6. Public information related to the reviewers

38. The names of the reviewers, their affiliation and comments will be made publicly available on the AOP-Wiki after completion of the review. The EAGMST recommends that the reviewers' names be provided as an AOP specific list, but not associated with their individual comments. This option was chosen as a compromise between having individual comments linked to individual reviewers (which some reviewers may not feel comfortable with as the comments become publicly available) and having a master list of reviewers across all AOPs (which may dilute the visibility of a reviewer's participation). The reviewers should be informed about this before the start of the review.

39. Reviewers are considered as critical contributors to AOP development and thus participation in the review of an AOP is regarded as a notable scholarly activity and achievement. Consequently, reviewers are encouraged to cite their contributions to the review of AOPs as part of their professional credentials (e.g., listed on a CV as evidence of scholarly activity and expertise).

## 4. Subsequent AOP endorsement by OECD

40. At the end of the review process, the authors of an AOP in the OECD AOP development work plan will be invited either by the review organiser or by the OECD Secretariat to revise their AOP in order to move to the next step, i.e. endorsement by OECD and subsequent publication of their AOP on the OECD public website. The AOP revision should take into consideration the comments from the Review panel and the AOP authors should provide written responses addressing the comments. Responses to reviewer comments will also be made publicly available on the AOP-Wiki.

41. The comments from the scientific review, responses from the AOP author, and the revised AOP are collated by the review organiser and submitted to EAGMST. EAGMST will then determine if the AOP can move to the next endorsement step. This decision is based on the verification that the recommendations from the scientific review have been adequately addressed in the revised AOP (any comments made at this stage are uploaded in the AOP discussion page in the AOP-Wiki). If this is the case, the AOP can be released to the WNT and the WPHA for endorsement by written procedure<sup>1</sup>. If this is not the case, further work may be needed from the AOP authors, as appropriate.

42. The OECD procedure that is described below applies to chemical-relevant AOPs and ionising radiations induced AOPs. Before their publication, AOPs may require other procedures for endorsement, depending on the overseeing regulatory bodies and the context of application.

43. The WNT and WPHA may consult their expert networks during the endorsement phase and questions or comments may be submitted to the AOP authors. The scope of AOP endorsement by the WNT and the WPHA was clarified in 2016, and the WNT and WPHA agreed on a disclaimer, which has subsequently been updated and which is included in the foreword of published AOPs:

---

<sup>1</sup> Regarding radiation-related or radiation-induced AOPs, the NEA CRPPH will be the standing Technical Committee in charge of the endorsement.

*“This Adverse Outcome Pathway (AOP) has been developed under the auspices of the OECD AOP Development Programme, overseen by the Extended Advisory Group on Molecular Screening and Toxicogenomics (EAGMST), which is an advisory group under the Working Group of the National Coordinators for the Test Guidelines Programme (WNT). The AOP has been reviewed internally by the EAGMST, its scientific review has been conducted following the principles established in the Guidance Document for the scientific review of Adverse Outcome Pathways, and it has been endorsed by [the WNT and the Working Party on Hazard Assessment (WPHA)]<sup>2</sup> [the Nuclear Energy Agency Committee of Radiological Protection and Public Health (CRPPH) in parallel to the WNT and the WPHA]<sup>3</sup>.”*

*Through endorsement of this AOP, [the WNT and the WPHA]<sup>2</sup> [the CRPPH, as well as the WNT and the WPHA]<sup>3</sup> express confidence in the scientific review process that the AOP has undergone and accept the recommendation of the EAGMST that the AOP be disseminated publicly. Endorsement does not necessarily indicate that the AOP is now considered a tool for direct regulatory application.”*

44. After WNT and WPHA endorsement, the last step in the AOP development process (as depicted in *Figure 2*), is declassification<sup>4</sup> by the OECD's Chemicals and Biotechnology Committee (CBC) followed by publication on the OECD public website on the [OECD Series on Adverse Outcome Pathways](#). As far as ionising radiation exposure is concerned in the AOP, after the CRPPH endorsement, the last step in the AOP development process is declassification by the NEA followed by publication on the [OECD Series on Adverse Outcome Pathways](#). The three-step endorsement of the AOP (EAGMST, WNT/WPHA and CBC) can involve further need for AOP authors to address OECD-specific revisions.

45. AOPs are viewed as living documents. Crowdsourcing is one principle of the AOP Development programme, and AOPs thus may continue to evolve on the AOP-KB after their OECD endorsement and publication, as new evidences supporting or rejecting AOPs are generated and/or new knowledge is gained. The purpose of publication in the Series on AOPs is to provide a stable version over time, i.e. the version which has been reviewed and revised based on the outcome of the review. An AOP published in the OECD series on AOPs may be considered for update when significant additional information is available in the AOP-Wiki that justifies the update.

---

<sup>2</sup> For AOPs induced by chemical stressors

<sup>3</sup> For AOPs induced by ionising radiations

<sup>4</sup> Official OECD information shall be either unclassified or classified as: a) For Official Use -- for information which should not be communicated except for official purposes; or b) Confidential -- for information the unauthorised disclosure of which would seriously prejudice the interest of the Organisation or any of its Member countries. When a classified official document under the responsibility of the CBC is ready for publication, the CBC is responsible for its declassification, such that it obtains an unclassified status and can be published.

# References

EFSA-ECHA (2018), Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009, *EFSA Journal* 16(6):5311, DOI: 10.2903/j.efsa.2018.5311

ICMJE<sup>5</sup> (2018), International Committee of Medical Journal Editors, Author Responsibilities—Conflicts of Interest [Webpage available at <http://www.icmje.org/recommendations/browse/roles-and-responsibilities/author-responsibilities--conflicts-of-interest.html> ]

National Academies, National Academy of Sciences, National Academy of Engineering, Institute of Medicine, National Research Council (2003), “Policy on committee composition and balance and conflicts of interest for committees used in the development of reports”. [Available at <https://www.nationalacademies.org/about/institutional-policies-and-procedures/conflict-of-interest-policies-and-procedures> ; *Policy on Committee Composition and Balance and Conflicts of Interest* ]

United Nations. SC-1/8: Rules of procedure for preventing and dealing with conflicts of interest relating to activities of the Persistent Organic Pollutants Review Committee [Available at (select SC-1/8 in the language of choice): <http://www.pops.int/%20TheConvention/POPsReviewCommittee/%20OverviewandMandate/tabid/2806/Default.aspx>]

World Health Organisation Declaration of Interests for WHO experts [Available at <https://www.who.int/about/doi-form-blank-en.doc?ua=1>]

OECD (2012), “The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins”, *OECD Series on Testing and Assessment*, No. 168, OECD Publishing, Paris.

OECD (2016a), “Guidance Document for the use of Adverse Outcome Pathways in developing Integrated Approaches to Testing and Assessment (IATA)”, *OECD Series on Testing and Assessment*, No. 260, OECD Publishing, Paris.

OECD (2016b), “Guidance Document on the Reporting of Defined Approaches and Individual Information Sources to be Used Within Integrated Approaches to Testing and Assessment (IATA) for Skin Sensitisation”, *OECD Series on Testing and Assessment*, No. 256, OECD Publishing, Paris.

OECD (2017), “Revised Guidance Document on Developing and Assessing Adverse Outcome Pathways”, *OECD Series on Testing and Assessment*, No. 184, OECD Publishing, Paris.

OECD (2018), “Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways”, *OECD Series on Adverse Outcome Pathways*, No. 1, OECD Publishing, Paris. <http://dx.doi.org/10.1787/5jlv1m9d1g32-en>

Frequently Asked Questions (FAQs): draft document

---

<sup>5</sup> International Committee of Medical Journal Editors

# Annex 1: Example of a template for the development of an AOP scientific review report

Foreword	6
Abbreviations	7
1. Background: The OECD AOP Development Programme	8
1.1. Objectives of the AOP Development Programme	8
1.2. Development of AOPs under the OECD AOP Development Programme	8
The role of the Extended Advisory Group for Molecular Screening and Toxicogenomics	9
The various steps and interlinkages between the parties involved in AOP development	10
2. Pre-requisite for the AOP scientific review	11
3. The AOP Scientific review	12
3.1. The management of the review: Review organiser and review manager	13
3.2. Conflict of interest	14
3.3. Call for reviewers and recruitment of candidate reviewers	14
3.4. Selection of reviewers from the pool of candidate reviewers	15
3.5. The review process	16
3.6. Public information related to the reviewers	17
4. Subsequent AOP endorsement by OECD	17
References	19

## Annex 2: Declaration of interest

### Conflict of Interest Questionnaire<sup>6</sup>:

The following questionnaire is intended to ensure that individuals who organise, manage, or participate in the scientific review of an adverse outcome pathway (AOP) are not compromised by any significant conflict of interest. Conflict of interest means any financial or other interest (including intellectual property) that conflicts with the participation of an individual in particular decisions and evaluation of the scientific content of an AOP because that interest could 1) impair the individual's objectivity or 2) create an unfair competitive advantage for any person or organisation.

Conflict of interest applies to the individual's personal interests, as well as to the interests of others with whom the individual has substantial common financial interests if these interests are relevant to the functions to be performed (e.g., consider individual's employer, business partners, spouse and other family members, etc). Consider also the interests for whom one is acting in a fiduciary or similar capacity (e.g., officer or director of a corporation, serving as a trustee).

The intent of the following questionnaire is to determine and eliminate certain potentially compromising situations from occurring, protecting the OECD and/or other institutions, individuals (organiser, manager, or reviewer), and the public interest.

A copy of the declaration should be retained that can be disclosed should questions of a conflict arise.

#### 1. Information:

1. Date:
2. Given Name:
3. Surname:
4. Role in review (organiser, manager, reviewer):
5. AOP number:
6. AOP title:

#### 2. Affiliations: please list your organisational affiliations (relevant business relationships and relevant remunerated or volunteer non-business relationships).

---

<sup>6</sup> THIS COI QUESTIONNAIRE WAS DEVELOPED BASED ON THE INTERNATIONAL COMMITTEE OF MEDICAL JOURNAL EDITORS (ICMJE) COI CHECKLIST ([HTTP://WWW.ICMJE.ORG/CONFLICTS-OF-INTEREST/](http://www.icmje.org/conflicts-of-interest/)) AND THE UNITED NATIONS PERSISTENT ORGANIC POLLUTANTS REVIEW COMMITTEE [RULES AND PROCEDURES FOR PREVENTING AND DEALING WITH CONFLICTS OF INTEREST RELATING TO ACTIVITIES OF THE PERSISTENT ORGANIC POLLUTANTS REVIEW COMMITTEE](#)..

3. Direct links to the AOP under consideration for scientific review: these questions are about links that existed at any time to the AOP under consideration including the stages of initial conception and planning to the present.
  1. Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc) for any aspect of the AOP under review (including but not limited to grants, data monitoring board, study design, AOP preparation/drafting, statistical analysis, etc.)? If yes, please list funders.
  2. Did you or your institution at any time directly fund or provide services (whether for free or for payment) for any aspect of the AOP under review (including but not limited to grants, data monitoring board, study design, AOP preparation/drafting, statistical analysis, etc.)? If yes, please explain.
  3. For a) and b) above, please list:
    1. Name of entity
    2. Type of funding (grant, personal fees, non-financial support, other)
    3. Provide any relevant comments
  4. If you have nothing to report, please state “Neither I nor any institution with which I am affiliated have received direct financial payment, financial or otherwise for work directly related to the development of the AOP under consideration for scientific review”
  
4. Relevant financial activities outside the AOP considered for scientific review: This section asks about financial interests outside of this AOP that could be perceived to influence, or give appearance of potentially influencing the scientific review, organisation, or management of the review of the AOP under review. All sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to review of the AOP under consideration (including all monies from sources with relevance to the specific AOP under review). Also list interactions with the AOP’s sponsor that are outside the submitted AOP. If unsure, you must disclose the relationship for review. For grants received related to the content of this AOP, you should disclose support from entities that could be impacted financially by publishing the AOP under review or that could reasonably be perceived to be affected financially by publishing the AOP under review. This section would include any conflicts of interest identified during current or previous employment by a government agency (e.g. national conflicts of interest restrictions that may be applicable to service in connection to this activity, is this project sponsored by your current government agency or other employer or sponsor?).
  1. Indicate whether you have financial relationships (regardless of the amount of compensation) with entities described above. List each entity you have had a relationship with in the last 36 months prior to this review process.
    1. Name of entity
    2. Type of funding (grant, personal fees, non-financial support, other)
    3. Provide any relevant comments
  2. If you have no financial activities outside of the AOP being considered for scientific review, please state “I have had no relevant financial relationships in the last 36 months outside the AOP being considered for scientific review”
  
5. Intellectual property – patents and copyright. Do you or your institution have any patents, whether planned, pending, or issued, that are relevant to this AOP?
  1. If yes, please list and describe.
  2. If no, please state, “I have no patents, planned, pending or issued that are relevant to the AOP to be reviewed”

6. Public statements and positions or other relevant aspects of your background or present circumstances not addressed that might be reasonably construed by others to affect your judgment in organising, managing or reviewing the AOP under consideration for scientific review. Please list any relevant articles, testimony, speeches, assigned tasks or activities that could be perceived to indicate a position on an issue or problem relevant to the AOP under consideration. Please list by date, title, and publication (if relevant) and a brief description of groups or activities of concern. If none, please state "None".
7. Lobbying activities. You must disclose any activities that are considered lobbying so that they can be considered for their potential relationship to the development and publishing of the AOP under scientific review. Lobbying activities are those that are performed by a person who receives compensation or reimbursement from another person, groups, or entity for the purpose of promoting, opposing, or in any manner influencing or attempting to influence the introduction, defeat, or enactment of legislation before any legislative body, or the practice of promoting, opposing, or in any manner influencing or attempting to influence the enactment, promulgation, modification, or deletion of regulations before any regulatory body (<http://www.ncsl.org/research/ethics/50-state-chart-lobby-definitions.aspx>). If none, please state "None".
8. Relationships not covered. Are there other relationships or activities that AOP users or the public at large could perceive to have influenced, or that give the appearance of potentially influencing your ability to organise, manage the review of, or review the AOP under consideration, e.g. participation in planned, ongoing or follow up research project collaborations dealing with AOP and respective test method development? Have you been involved in the development of the AOP at any stage?
1. If yes, please list and describe, e.g. possible influence by governmental deadlines, priorities or programs, colleagues, or program pressures, friends on staffs of journals/publications
  2. If no, please state "No other relationships, considerations, or circumstances exist that present a potential conflict of interest".

**Disclosure statement:**

**NAME HERE** has the following potential conflicts to disclose related to the **LIST AOP TITLE AND NUMBER HERE**:

OR

**NAME HERE** has nothing to disclose.

I understand that any inaccuracies or omissions, whether intentional or unintentional, could have a serious impact not only on the AOP being reviewed but on the AOP programme and the OECD more generally. I confirm that I have carefully read and understood the above questions and that my responses above are accurate and complete and do not contain any misleading statements or information. If I at any point before completion of the AOP review realise that I have omitted information from this form, I will immediately contact  in order to update this form.

\_\_\_\_\_  
Signature of organiser, review manager, or reviewer

\_\_\_\_\_  
Date